Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bedside Genetic Approach to Identify Clopidogrel CYP2C19 Metabolizer and Optimize Maintenance Thienopyridine Treatment After an Acute Coronary Syndrome: The GAMMA Study

NCT01390974 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.

NCT NCT01390974
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01390974 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bedside Genetic Approach to Identify Clopidogrel CYP2C19 Metabolizer and Optimize Maintenance Thienopyridine Treatment After an Acute Coronary Syndrome: The GAMMA Study
Lead sponsor
Assistance Publique - Hôpitaux de Paris
Phase
Observational
Overall status
Completed
Start date
July 31, 2011
Completion date
November 30, 2012
Enrollment
270 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome